CALGARY, Canada - (NewMediaWire) - May 27, 2024 - Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (USA: VYYRF) ("Voyageur" or the "Company") proudly announces signing its first sales contract valued at USD $1.9 million (approximately CAD $2.6). The contract is over a three-year term, with a distribution partner who sells radiology drugs in the territories of Latin America. The contract is for distribution in two countries and will begin after drug license approvals are granted. The distribution company gains exclusivity in the territories by paying for all regulatory and licensing costs. The contract pricing is based on hitting volume milestones.
This major sales distribution agreement will allow Voyageur to market its products across Latin America, leverage SmoothX as our lead entry product and open the door to increased sales of our other five products, Vision HD(R) 98%, Vision LD(R) 96%, Smooth HD(R) 105%, Smooth LD(R) 60%, and V-Gas(R).
Voyageur is introducing a comprehensive suite of five new Health Canada licensed products, set to diversify the medical imaging landscape in both Canadian and international markets. Comprising two distinct brands - Vision and Smooth - Voyageur's latest offerings promise performance and versatility in medical diagnostics. V-Gas is under development and is used as an integral component in double contrast studies.
Voyageur SmoothX(R)2% w/v is available for immediate sales and distribution. It is a contrast media for use in Computed Tomography (CT) of the gastrointestinal tract. The Company's barium supports high-quality imaging with reproducible results for accurate diagnosis and image comparison. In clinical tests many patients preferred the taste of SmoothX over the product currently used in CT imaging.
The upcoming product releases, slated for market debut, pending the conclusion of performance testing, include:
Vision HD(R) 98%: Engineered as a high-density (98% w/w) barium powder suspension, VisionHD is tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum in adult and pediatric patients.
Vision LD(R) 96%: Boasting exceptional versatility, VisionLD is a high-density (57% w/w to 156% w/w) barium powder suspension for single contrast radiographic examinations of the esophagus, stomach, duodenum and small bowel to visualize the gastrointestinal tract (GI) in adult and pediatric patients.
Smooth HD(R) 105%: Designed for upper GI esophagogram and double contrast studies of the upper and lower gastrointestinal tract and colon, SmoothHD delivers clarity and detail with its high-density (105% w/v, 58% w/w) barium suspension formulation, catering to the diagnostic needs of both adults and children.
Smooth LD(R) 60%: Offering a low-density (60% w/v) barium suspension solution, SmoothLD is tailored for single contrast radiographic examinations of the esophagus, stomach, and small bowel to visualize the gastrointestinal (GI) tract, providing reliable results for patients across all age groups.
V-Gas(R) - Under Development: In addition to the existing product lineup, Voyageur is actively developing V-Gas Effervescent Granules (4g), an innovative antacid and antiflatulent solution poised to alleviate common digestive discomforts while also serving as an integral component in double contrast studies. V-Gas is indicated for use in adults and children.
Having already made significant strides in marketing its product lines to industry stakeholders, Voyageur remains steadfast in its commitment to providing solutions to its expanding clientele. With the impending completion of clinical testing for the remaining products, the Company is poised to offer a comprehensive suite of diagnostic solutions to meet the diverse needs of healthcare professionals worldwide.
All contract details are strictly confidential, due to the highly competitive landscape of a monopolised barium contrast industry. This market dynamic opens an accessible market for Voyageur which is looking for innovation and new product options for healthcare institutions and companies looking to diversify their product lines. The estimated contract value has been determined based on management's expectations with respect to sales volumes during the term of the contract.
For further details on Voyageur's innovative product offerings and to secure pre-market orders, please visit our official website at https://voyageurpharmaceuticals.ca.
About Voyageur Pharmaceuticals Ltd.
Voyageur, a Canadian public company trading under the symbol VM on the TSXV, is in development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance, cost-effective imaging contrast agents. With a strategic focus on vertically integrating the barium and iodine contrast market, Voyageur aims to become a key player by producing its own barium, iodine, and fullerene minerals.
Voyageur's business plan is set to generate cash flow by partnering with established third-party GMP pharmaceutical manufacturers in Canada, ensuring the validation of its products by regulatory agencies worldwide. As Voyageur solidifies its presence in the market, it plans to transition into a high-margin domestic manufacturer of radiology drugs, further expanding its revenue streams.
Voyageur is committed to sustainability and environmental stewardship. Voyageur envisions a future where carbon neutrality is the norm, and to achieve this, it is building state-of-the-art carbon-neutral infrastructure utilising the Rain Cage EDENTM system. By investing in carbon neutral energy sources and sustainable manufacturing practices, Voyageur aims to increase revenue from carbon capture to accelerate growth. Voyageur's unwavering commitment to the environment sets it apart as a pioneer in the industry.
At the core of its operations, Voyageur owns a 100% interest in the Frances Creek barium sulphate (barite) project. This project boasts exceptional grade minerals suitable for the pharmaceutical marketplace.
Voyageur's ambitious vision is to become the first vertically integrated, carbon-neutral company in the radiology contrast media drug market. By controlling all primary input costs, from the sourcing of raw materials to the final production, Voyageur ensures quality and cost efficiency. With its approach, it embodies the motto of "From the Earth to the Bottle," highlighting Voyageur's commitment to responsible sourcing and manufacturing practices.
For Further Information:
Brent Willis, CEO
Brent@vpharma.ca, 403-923-5944
info@vpharma.ca
Albert Deslauriers, CFO
Albert@vpharma.ca
https://voyageurpharmaceuticals.ca
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Cautionary Statement Regarding "Forward-Looking" Information
This news release may contain certain forward-looking information and statements, including without limitation, statements pertaining to: the realizable value to Voyageur from the sales contract; the expectation that Voyageur will obtain drug license approvals; market acceptance and sales for the suite of five new licensed products and SmoothX; the successful completion of the clinical testing for the remaining four products; the Rain Cage EDENTM technology being carbon neutral; and availability of financing. All statements included herein, other than statements of historical fact, are forward-looking information and such information involves various risks and uncertainties. There can be no assurance that such information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in the Company's disclosure documents on the SEDAR+ website at www.sedarplus.ca. Voyageur does not undertake to update any forward-looking information except in accordance with applicable securities laws.
